Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

Clinical trial NCT05020392 · UNKNOWN

Trial details

NCT number: NCT05020392
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Diffuse Large B Cell Lymphoma Burkitt Lymphoma Follicular Lymphoma Chronic Lymphocytic Leukemia Mantle Cell Lymphoma

Start date: 2021-09-14
Primary completion: 2023-10-13
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.